This platform will be developed in a modular format, which will allow each module to be developed and exploited individually. The modules will subsequently be integrated to facilitate the desired application. Advances in data communications, molecular biology and biosensor technology, with the integration of nanostructured functional components in macro and microsystems, will facilitate the realisation of a minimally invasive generic platform, which is capable of multi-parametric monitoring and will be interoperable with electronic medical records.
The advantages of integrated biosensor systems include their ease of use, their sensitivity, their inherent selectivity (preventing problems due to interfering substances), their versatility (allowing `in-field¿ use) and their cost effectiveness. Addressing the future health care requirement of an individualised theranostic approach, the specific application that will be demonstrated in this IP will be for the management, monitoring and diagnosis of coeliac disease, with the proposed technology contributing to significant advances in sensitivity and specificity of diagnosis. The technology platform developed, however, could be applied to a variety of clinical screening applications, such as cancer. The radical innovation proposed in this IP will result in a concrete prime deliverable of a technology platform of wide application and unquestionable socio-economic benefit, increasing European competitiveness whilst contributing considerably to the quality of life well being of the population.
For further information, please visit:
http://www.cdmedics.eu
Project co-ordinator:
Universitat Rovira i Virgili
Partners:
- Institut für Mikrotechnik Mainz GmbH
- Microfluidic ChipShop GmbH
- Newcastle University
- Intracom Telecom solutions
- Clemens GmbH
- Micro2Gen
- Eurospital SpA
- King's College London Business Ltd
- INNO-TRAIN Diagnostik GmbH
- TATAA Biocenter
- MultiD Analyses AB
- Finnish Red Cross Blood Service
- Fondazione IRCCS Policlinico San Matteo
- University Medical Centre Maribor
- Valentia Technologies Limited
- Association of European Coeliac Societies
- Coeliac UK
- Asociación de celíacos de Madrid
- iXscient Ltd.
- Newcastle upon Tyne Hospitals NHS Foundation Trust
Timetable: from 01/2008 to 12/2011
Total cost: 12.796.559
EC funding: 9.500.000
Programme Acronym: FP7-ICT
Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics
Contract type: Collaborative project (generic)
Related news article:
